The test is currently in clinical trials at several medical centers including Rochester, Minn.-based Mayo Clinic, Houston Methodist Hospital and Ann Arbor-based University of Michigan.
Mr. Carlson will manage logistics of the release, including commercialization strategy and FDA marketing authorization.
The InFoods test involves patient blood collection and looks for immunoreactivity to specific foods.
Physicians can then determine which foods patients should remove from their diets to relieve IBS symptoms.
“We have seen very positive responses from GI physicians about using InFoods IBS as a tool to help patients manage the multiple and challenging symptoms of IBS,” Zack Irani, Biomerica’s CEO, said in an Aug. 30 press release from the company. “After several years of extensive development, testing, validation and clinical trials of our patented InFoods technology platform, we’re excited to now be launching the InFoods IBS test.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
